This trial will offer patients immunotherapy treatment instead of multi-agent chemotherapy to try and cure their disease. The trial will combine Pembrolizumab, an immunotherapy drug, with one of the single chemotherapy drugs normally used to treat this cancer. It is already used to treat other cancers such as melanoma and kidney cancer.
Immunotherapy is a type of cancer treatment that helps your immune system to fight cancer. It helps your immune system to recognise and fight cancer cells. Immunotherapy educates the immune system to recognise and attack specific cancer cells and boost immune cells to help them eliminate cancer.
It is far less toxic than traditional multi-agent chemotherapy treatment and has fewer side effects. We expect this trial will save patients from having to endure the toxicity of multi-agent chemotherapy and cure their cancer.